D'Incalci M - Search Results

1

The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.

D'Angelo D, Borbone E, Palmieri D, Uboldi S, Esposito F, Frapolli R, Pacelli R, D'Incalci M, Fusco A. D'Angelo D, et al. Eur J Cancer. 2013 Mar;49(5):1142-51. doi: 10.1016/j.ejca.2012.10.014. Epub 2012 Nov 10. Eur J Cancer. 2013. PMID: 23149213

2

Pharmacokinetics of anticancer agents in patients with impaired liver function.

Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Donelli MG, et al. Eur J Cancer. 1998 Jan;34(1):33-46. doi: 10.1016/s0959-8049(97)00340-7. Eur J Cancer. 1998. PMID: 9624235 Review.

3

Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.

Damia G, Guidi G, D'Incalci M. Damia G, et al. Eur J Cancer. 1998 Oct;34(11):1783-8. doi: 10.1016/s0959-8049(98)00190-7. Eur J Cancer. 1998. PMID: 9893669

4

High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma.

Colombo T, Frapolli R, Bombardelli E, Morazzoni P, Riva A, D'Incalci M, Zucchetti M. Colombo T, et al. J Chromatogr B Biomed Sci Appl. 1999 Dec 24;736(1-2):135-41. doi: 10.1016/s0378-4347(99)00450-8. J Chromatogr B Biomed Sci Appl. 1999. PMID: 10676993

5

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, Mantovani R. Minuzzo M, et al. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6780-4. doi: 10.1073/pnas.97.12.6780. Proc Natl Acad Sci U S A. 2000. PMID: 10841573 Free PMC article.

6

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M. Erba E, et al. Eur J Cancer. 2001 Jan;37(1):97-105. doi: 10.1016/s0959-8049(00)00357-9. Eur J Cancer. 2001. PMID: 11165136

7

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M. Gambacorti-Passerini C, et al. Clin Cancer Res. 2003 Feb;9(2):625-32. Clin Cancer Res. 2003. PMID: 12576428 Clinical Trial.

8

IDN 5390: an oral taxane candidate for protracted treatment schedules.

Pratesi G, Laccabue D, Lanzi C, Cassinelli G, Supino R, Zucchetti M, Frapolli R, D'Incalci M, Bombardelli E, Morazzoni P, Riva A, Zunino F. Pratesi G, et al. Br J Cancer. 2003 Mar 24;88(6):965-72. doi: 10.1038/sj.bjc.6600784. Br J Cancer. 2003. PMID: 12644838 Free PMC article.

9

The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT. D'Incalci M, et al. Eur J Cancer. 2003 Sep;39(13):1920-6. doi: 10.1016/s0959-8049(03)00490-8. Eur J Cancer. 2003. PMID: 12932672

10

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.

Donald S, Verschoyle RD, Greaves P, Gant TW, Colombo T, Zaffaroni M, Frapolli R, Zucchetti M, D'Incalci M, Meco D, Riccardi R, Lopez-Lazaro L, Jimeno J, Gescher AJ. Donald S, et al. Cancer Res. 2003 Sep 15;63(18):5902-8. Cancer Res. 2003. PMID: 14522916

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

564 results

Search Page

Filters